Sign in

Private company

CASI Pharmaceuticals, Inc (DE)

CASI Pharmaceuticals, Inc (DE) is an American biological products company, incorporated in Delaware.1 It is headquartered in Rockville, Maryland.1

Last updated Oct 21, 2026.

Overview

$38.0MRevenue, fiscal 20222
-$41.0MNet income, fiscal 20222
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersRockville, Maryland1
  • Incorporated inDE3
  • Business address9620 Medical Center Dr, Ste 300, Rockville, Md 208503
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-89.4%Operating margin2
-107.8%Net margin2
26.7%Revenue growth, 20222
-92.0%Return on equity2
-$26.7MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue42¢$15.8M
  • Other costs53¢$20.2M
  • Income tax5¢$2.0M

Out of $38.0M in revenue.2 The company lost money this year.

Financial statements

Revenue456782$38.0M in 2022+79643% since 2015
0$10.0M$20.0M$30.0M$40.0M2015: $47.7K$47.7K20152016: $0$020162017: $0$020172018: $0$020182019: $4.1M$4.1M20192020: $15.0M$15.0M2020+269%2021: $30.0M$30.0M2021+100%2022: $38.0M$38.0M2022+27%
Gross profit9$17.6M in 2021+213% since 2020
0$5.0M$10.0M$15.0M$20.0M2020: $5.6M$5.6M20202021: $17.6M$17.6M2021+213%
Operating income782-$34.0M in 2022+25% since 2018
-$60.0M-$40.0M-$20.0M02018: -$27.2M-$27.2M20182019: -$47.0M-$47.0M2019+73%2020: -$52.8M-$52.8M2020+12%2021: -$41.5M-$41.5M2021−21%2022: -$34.0M-$34.0M2022−18%
Net income456782-$41.0M in 2022+469% since 2015
-$60.0M-$40.0M-$20.0M02015: -$7.2M-$7.2M20152016: -$9.5M-$9.5M2016+31%2017: -$10.8M-$10.8M2017+14%2018: -$27.5M-$27.5M2018+155%2019: -$46.0M-$46.0M2019+68%2020: -$48.3M-$48.3M2020+5%2021: -$36.7M-$36.7M2021−24%2022: -$41.0M-$41.0M2022+12%
Fiscal year20152016201720182019202020212022
Revenue$47.7K4$05$06$07$4.1M8$15.0M2$30.0M2$38.0M2
Cost of revenue$6.3K4$04$07$3.9M8$9.5M2$12.6M2$15.8M2
Gross profit$5.6M9$17.6M9
Research and development$4.1M4$4.6M5$7.6M6$8.5M7$9.7M7
Operating expenses$59.1M2$61.3M2
Operating income-$27.2M7-$47.0M8-$52.8M2-$41.5M2-$34.0M2
Interest$7.5K6$7.5K7$5.6K7$3.1K2$2.9K2$02
Income before tax-$35.8M9-$37.4M2
Income tax$04$05$06$07$08$02$02$2.0M2
Net income-$7.2M4-$9.5M5-$10.8M6-$27.5M7-$46.0M8-$48.3M2-$36.7M2-$41.0M2
Earnings per share-$0.449-$0.279
Earnings per share (diluted)-$0.449-$0.279
Shares (weighted, basic)13.6M shares213.6M shares2
Shares (weighted, diluted)13.6M shares213.6M shares2

Compare CASI Pharmaceuticals, Inc (DE) with another company

Corporate structure

CASI Pharmaceuticals, Inc (DE) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CASI Pharmaceuticals, Inc (DE)

  • SPARKLE BYTE LTD Filed SC 13D/A on CASI Pharmaceuticals, Inc (DE), latest Feb 20, 2024
  • Chi Sing Ho Filed SC 13D/A on CASI Pharmaceuticals, Inc (DE), latest Feb 21, 2023
  • Federated Hermes Filed SC 13G/A on CASI Pharmaceuticals, Inc (DE), latest Feb 9, 2023 (3 filings since Feb 14, 2022)
  • Wei-Wu He Filed SC 13D/A on CASI Pharmaceuticals, Inc (DE), latest Jun 21, 2022 (2 filings since Nov 23, 2021)
  • Consonance Capital Management LP Filed SC 13G/A on CASI Pharmaceuticals, Inc (DE), latest Feb 14, 2022
  • CASI Pharmaceuticals, Inc (DE) Rockville, Maryland

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CASI Pharmaceuticals, Inc (DE) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Leasehold improvements$7.2M2 Dec 31, 2022$1.1M2 Dec 31, 2021+532.0%
Construction in progress$5.7M2 Dec 31, 2022$12.1M2 Dec 31, 2021−52.6%
Property and equipment, before depreciation$14.1M2 Dec 31, 2022$15.0M2 Dec 31, 2021−5.5%
Accumulated depreciation$2.3M2 Dec 31, 2022$1.8M2 Dec 31, 2021+26.5%
Property and equipment, net$11.8M2 Dec 31, 2022$12.7M2 Dec 31, 2021−6.9%
Operating-lease assets (leased space)$1.4M2 Dec 31, 2022$9.1M2 Dec 31, 2021−84.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$47.1M2 Dec 31, 2022$38.7M2 Dec 31, 2021+21.7%
Marketable securities, current$2.8M2 Dec 31, 2022$9.9M2 Dec 31, 2021−72.0%
Long-term investments$4.4M2 Dec 31, 2022$40.1M2 Dec 31, 2021−89.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.1M2 Dec 31, 2022$12.2M2 Dec 31, 2021−91.3%
Finite-lived intangibles, gross$16.1M2 Dec 31, 2022$16.0M2 Dec 31, 2021+0.3%
Accumulated amortization$6.3M2 Dec 31, 2022$3.8M2 Dec 31, 2021+64.4%
Finite-lived intangibles, net$1.1M2 Dec 31, 2022$12.2M2 Dec 31, 2021−91.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$6.1M2 Dec 31, 2022$1.9M2 Dec 31, 2021+221.9%
Finished goods$6.1M2 Dec 31, 2022$1.9M2 Dec 31, 2021+221.1%

Leadership

Who has led CASI Pharmaceuticals, Inc (DE), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ken Ren2016

President

  1. Larry Zhang2018–2021

Chief financial officer

  1. Dane R. Saglio2006–2008
  2. George Chi2018

Chief operating officer

  1. Cynthia Wong2009–2019
2010201520202025
Board members and other officers (23)

Former names

  • CASI Pharmaceuticals, Inc.Aug 14, 2014 to Feb 21, 20233
  • ENTREMED INCMay 14, 1996 to Jun 13, 20143

Timeline

  1. Mar 21, 20238-K Shareholder vote; Other events41
  2. Jan 31, 20238-K Entered a material agreement42
  3. Nov 14, 20228-K Results of operations43
  4. Sep 23, 20228-K Entered a material agreement44
  5. Aug 12, 20228-K Results of operations45
  6. May 26, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events46
  7. May 25, 20228-K Shareholder vote47
  8. May 25, 20228-K Other events48
  9. May 24, 20228-K Entered a material agreement49
  10. May 24, 20228-K Entered a material agreement; New debt or obligation50
  11. May 12, 20228-K Results of operations51
  12. May 2, 20228-K Other events52
  13. Jan 21, 2016New chief executive Ken Ren becomes CEO14

Calendar

When it reported results

  1. Nov 14, 2022Reported quarterly or annual results43
  2. Aug 12, 2022Reported quarterly or annual results45
  3. May 12, 2022Reported quarterly or annual results51
  4. Mar 28, 2022Reported quarterly or annual results53
  5. Feb 16, 2022Reported quarterly or annual results54
  6. Nov 12, 2021Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

58 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 20 major events, 13 insider forms, 8 large holders, 12 other. The latest 20:

  1. Feb 20, 2024SC 13D/A EDGAR
  2. Mar 24, 2023EFFECT EDGAR
  3. Mar 22, 202315-12G EDGAR
  4. Mar 21, 2023POS AM EDGAR
  5. Mar 21, 20238-K EDGAR
  6. Feb 21, 2023SC 13D/A EDGAR
  7. Feb 14, 2023DEF 14A EDGAR
  8. Feb 9, 2023SC 13G/A EDGAR
  9. Feb 1, 2023SC 13G/A EDGAR
  10. Jan 31, 20238-K EDGAR
  11. Jan 30, 2023UPLOAD EDGAR
  12. Jan 19, 2023CORRESP EDGAR
  13. Jan 6, 2023UPLOAD EDGAR
  14. Dec 16, 2022CORRESP EDGAR
  15. Dec 7, 2022UPLOAD EDGAR
  16. Nov 14, 202210-Q EDGAR
  17. Nov 14, 20228-K EDGAR
  18. Sep 23, 20228-K EDGAR
  19. Sep 9, 20224 OWNERSHIP DOCUMENT EDGAR
  20. Sep 8, 20224 FORM 4 SUBMISSION EDGAR

The 58 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 16 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 8, 2022Huang JamesDirectorBuy33,300$4.28$142.5KForm 4
Sep 7, 2022Huang JamesDirectorBuy3,111$4.00$12.4KForm 4
Sep 6, 2022Huang JamesDirectorBuy19,162$3.89$74.5KForm 4
Sep 2, 2022Huang JamesDirectorBuy400$3.74$1.5KForm 4
Sep 1, 2022Huang JamesDirectorBuy11,821$3.72$44.0KForm 4
Aug 31, 2022Huang JamesDirectorBuy24,975$3.75$93.7KForm 4
Aug 26, 2022Huang JamesDirectorBuy39,527$3.75$148.2KForm 4
Aug 24, 2022Huang JamesDirectorBuy5,000$3.75$18.8KForm 4
Aug 23, 2022Huang JamesDirectorBuy40,000$3.50$140.0KForm 4
Aug 22, 2022Huang JamesDirectorBuy23,105$3.46$79.9KForm 4
Aug 19, 2022Huang JamesDirectorBuy171,116$3.27$559.5KForm 4
Jun 15, 2022He Wei-WuChairman and CEOBuy50,000$3.18$159.0KForm 4
Jun 14, 2022He Wei-WuChairman and CEOBuy2,096$3.06$6.4KForm 4
Jun 13, 2022He Wei-WuChairman and CEOBuy36,058$2.97$107.1KForm 4
Nov 18, 2021He Wei-WuChairman and CEOBuy200,000$0.98$196.0KForm 4
Nov 17, 2021He Wei-WuChairman and CEOBuy200,000$0.99$198.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CASI Pharmaceuticals, Inc (DE) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCASI Pharmaceuticals, Inc (DE)1
  • CIK0000895051
  • Employer ID (EIN)58-19594401
  • Filer statusNon-accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9620 Medical Center Dr, Ste 300, Rockville, MD 208501
  • Phone240-864-26001
  • Shares outstanding13,457,625 as of Dec 31, 20222
  • Public float$179.2M as of Jun 30, 20219
  • On EDGAR sinceMay 14, 19961
  • Filings947 in all: 4 (276), 8-K (227), 10-Q (79), 3 (29), DEF 14A (28), SC 13D/A (28), S-3 (24), 424B5 (23)1
    All 42 form types

    10-K (21), SC 13G (20), CORRESP (19), SC 13G/A (19), UPLOAD (18), EFFECT (14), S-3/A (14), PRE 14A (12), 424B3 (9), S-8 (9), SC 13D (8), 10-K/A (7), 8-K/A (7), S-8 POS (7), 424B2 (6), 10-K405 (5), 10-Q/A (5), CT ORDER (5), 10-K405/A (4), REGDEX (4), S-1/A (3), 4/A (2), DEFA14A (2), NT 10-K (2), SEC STAFF LETTER (2), 10QSB (1), 15-12G (1), 424B1 (1), 8-A12G (1), ARS (1), D (1), NT 10-Q (1), POS AM (1), PX14A6G (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2022
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Feb 14, 2023
    Latest 8-K (8-K) Mar 21, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60